We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+73.87%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$155M
AUM Growth
+$31.6M
Cap. Flow
-$17.5M
Cap. Flow %
-11.27%
Top 10 Hldgs %
99.2%
Holding
14
New
–
Increased
1
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$3.1M

Top Sells

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$6.33M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.03M
3
KRON
Kronos Bio
KRON
+$3.26M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$2.88M
5
NUVB icon
Nuvation Bio
NUVB
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$51.2M 33.05%
14,072,340
-1,000,000
-7% -$1.92M
LXEO icon
2
Lexeo Therapeutics
LXEO
$366M
$36.9M 23.83%
2,355,904
+198,281
+9% +$3.1M
REPL icon
3
Replimune Group
REPL
$814M
$24.5M 15.82%
3,001,319
– –
ENGN icon
4
enGene Therapeutics
ENGN
$122M
$18.2M 11.77%
1,076,357
-54,818
-5% -$671K
SANA icon
5
Sana Biotechnology
SANA
$885M
$8.44M 5.44%
843,750
– –
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.63M 3.63%
159,846
-150,000
-48% -$5.03M
IMA
7
ImageneBio Inc
IMA
$63.1M
$3.19M 2.06%
187,427
– –
IMUX icon
8
Immunic
IMUX
$182M
$2.36M 1.52%
178,816
– –
ENGNW icon
9
enGene Therapeutics Warrants
ENGNW
$3.75M
$1.88M 1.21%
360,903
-114,174
-24% -$348K
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.34M 0.87%
251,270
– –
KRON
11
DELISTED
Kronos Bio
KRON
$1.24M 0.8%
955,866
-2,862,417
-75% -$3.26M
SNTI icon
12
Senti Biosciences Holdings
SNTI
$12.6M
– –
-19,579
Closed -$129K
SPRB
13
Spruce Biosciences
SPRB
$119M
– –
-28,814
Closed -$6.33M
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-711,479
Closed -$2.88M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2024 Portfolio in Review

As of Q1 2024, Omega Fund Management held 14 positions worth $155M, up 26% from $123M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Omega Fund Management withdrew a net $17.5M in Q1 2024, closing 3 positions and reducing 5 holdings. Its most notable exit was Spruce Biosciences, an estimated $6.33M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Omega Fund Management added an estimated $3.1M to Lexeo Therapeutics.

  • Omega Fund Management added most to Lexeo Therapeutics in Q1 2024, an estimated $3.1M increase.
  • Omega Fund Management's biggest Q1 2024 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $5.03M.
  • Omega Fund Management fully exited Spruce Biosciences in Q1 2024, selling an estimated $6.33M.
  • Omega Fund Management's ten largest holdings make up 99% of its $155M portfolio in Q1 2024.
  • Omega Fund Management opened 0 new positions and closed 3 in Q1 2024.
  • Omega Fund Management's portfolio value rose 26% quarter-over-quarter to $155M.

Based on Omega Fund Management's 13F filing for Q1 2024, filed 14 May 2024.